vindesine

Phase 3Small molecule

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

vindesine is one of 339 small molecule programs targeting Lymphoblastic Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

338

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoblastic LymphomaActive, not recruiting

Lung CancerActive, not recruiting

Anaplastic Large Cell LymphomaActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

NeuroblastomaActive, not recruiting

Lung NeoplasmActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Lymphoblastic LymphomaPhase 3

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 3

Active, not recruiting

NeuroblastomaPhase 3

Active, not recruiting

Lung NeoplasmPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

vindesine

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

7 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Newly Diagnosed

NCT06361329

Q4 2027

Phase 3Recruiting

Lymphoblastic Lymphoma

NCT04043494

Q3 2028

Phase 3Recruiting

Acute Lymphoblastic Leukemia

NCT03643276

Q3 2030

Phase 2Recruiting

Newly Diagnosed

NCT07159620

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia10 trials

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003728·1,500 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed·GGoethe University·Phase 4·NCT00198991·1,883 enrolled

Show 7 more trials

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting·MMartin Schrappe·Phase 3·NCT03643276·5,000 enrolled

Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown status·—·Phase 3·NCT00764907·4,000 enrolled

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT01156883·76 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT00430118·4,559 enrolled

Lymphoma7 trials

Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT02767674·258 enrolled

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Unknown status·PPETHEMA Foundation·Phase 2·NCT05049473·100 enrolled

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00136565·60 enrolled

Show 4 more trials

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04899570·20 enrolled

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT02987244·100 enrolled

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Terminated·FFrench Innovative Leukemia Organisation·Phase 3·NCT00920153·442 enrolled

Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Unknown status·XXinjiang Medical University·Phase 2/3·NCT02871869·316 enrolled

Neuroblastoma5 trials

Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Completed·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 2·NCT00017225

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·N/A·NCT00526318·360 enrolled

Show 2 more trials

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 3·NCT00410631·642 enrolled

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Completed·—·Phase 3·NCT00002802·500 enrolled

Non-Small Cell Lung Cancer3 trials

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00002823·3,300 enrolled

Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 3·NCT00003240·1,800 enrolled

Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer

Unknown status·OOttawa Regional Cancer Centre·Phase 1·NCT00002887·30 enrolled

Leukemia2 trials

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Unknown status·HHannover Medical School·Phase 2·NCT00002532

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00002531

6 more indications

Lymphoblastic Lymphoma2 trials

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199017·75 enrolled

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting·UUniversity Hospital Muenster·Phase 3·NCT04043494·683 enrolled

Newly Diagnosed2 trials

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07159620·27 enrolled

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT06361329·81 enrolled

Diffuse Large B-Cell Lymphoma2 trials

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Terminated·LLymphoma Study Association·Phase 3·NCT00135499·138 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

Unknown status·UUniversity Hospital Southampton NHS Foundation Trust·N/A·NCT00689845·120 enrolled

Cervical Cancer1 trial

Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003209·700 enrolled

DLBCL1 trial

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03018626·402 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 36 trial records for vindesine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vindesine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vindesine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — German Society for Pediatric Oncology and Hematology GPOH gGmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

vindesine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q3 2028

Q3 2030

Trials by Indication[1]

Acute Lymphoblastic Leukemia10 trials

Lymphoma7 trials

Neuroblastoma5 trials

Non-Small Cell Lung Cancer3 trials

Leukemia2 trials

Lymphoblastic Lymphoma2 trials

Newly Diagnosed2 trials

Diffuse Large B-Cell Lymphoma2 trials

Cervical Cancer1 trial

DLBCL1 trial

Anaplastic Large Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News